Objective: Abnormal B cell lymphoma-2 (Bcl-2) and interleukin-19 (IL-19) expression is closely related to systemic lupus erythematosus (SLE) pathogenesis. We aimed to determine whether polymorphisms and a single nucleotide polymorphism (SNP) of are significantly associated with SLE susceptibility and if this is affected by synergism between and genotypes.
Methods: This observational cohort study randomly enrolled 150 patients with SLE and 150 healthy controls. Major and allele and genotype distributions were examined in the two groups. The SNP rs2243188 was determined using the TaqMan-MGB probe method. The synergistic effect between and and clinical symptoms of SLE was also analyzed.
Results: The distribution of major genotypes and common alleles, especially for genotypes 191, 193, and 197, differed significantly between patients and controls. A significant difference in the dominant genetic model was also observed between groups, but not in the recessive model. The risk of disease in individuals who carried both 195-bp and 138-bp susceptibility alleles was higher than in those carrying either allele alone.
Conclusions: This preliminary study suggested that polymorphisms and the SNP rs2243188 are closely related to the pathogenesis of SLE.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165844 | PMC |
http://dx.doi.org/10.1177/03000605211019187 | DOI Listing |
Monoclon Antib Immunodiagn Immunother
January 2025
Department of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
CD300a and CD300A, among the CD300 immunoglobulin (Ig)-like receptor family members in mice and humans, respectively, are expressed on myeloid cell lineage. The interaction of CD300a and CD300A with their ligands phosphatidylserine and phosphatidylethanolamine, respectively, exposed on the plasma membrane of dead cells mediate an inhibitory signal in myeloid cells. We previously reported that a neutralizing antimouse CD300a monoclonal antibody (mAb) enhanced efferocytosis by macrophages and ameliorated acute ischemic stroke (AIS) in mice.
View Article and Find Full Text PDFEgypt J Immunol
January 2025
Department of Clinical Pathology, Faculty of Medicine Ain Shams University, Cairo, Egypt.
The worldwide incidence of colorectal cancer (CRC) is roughly two million new instances each year throughout the world, according to the World Health Organization 2022. CRC is the third most prevalent disease and the second most common cancer in terms of fatality. People diagnosed with colorectal cancer in the early stages have a five-year survival rate of roughly 95%, but people identified with the disease in the later stages have a survival rate of approximately 12%.
View Article and Find Full Text PDFEgypt J Immunol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Psoriasis (PsO) is a chronic immune-mediated disease of the skin. Psoriatic arthritis (PsA) is a prevalent chronic inflammatory disease that is associated with joint destruction and disability. The presence of PsO is the single greatest risk factor for the development of PsA.
View Article and Find Full Text PDFJ Evol Biol
January 2025
ISTA (Institute of Science and Technology Austria), Am Campus 1, 3400 Klosterneuburg, Austria.
Polymorphic short insertions and deletions (INDELs ≤ 50 bp) are abundant, although less common than single nucleotide polymorphisms (SNPs). Evidence from model organisms shows INDELs to be more strongly influenced by purifying selection than SNPs. Partly for this reason, INDELs are rarely used as markers for demographic processes or to detect divergent selection.
View Article and Find Full Text PDFRNA secondary (2D) structure visualisation is an essential tool for understanding RNA function. R2DT is a software package designed to visualise RNA 2D structures in consistent, recognisable, and reproducible layouts. The latest release, R2DT 2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!